The effects of adding palbociclib to endocrine therapy to treat advanced breast cancer: a plain language summary of a study using the PALOMA-2 and PALOMA-3 trial results

By sjmartinez • November 2, 2023

Rugo HS, Im SA, Joy AA, Shparyk Y, Walshe JM, Sleckman B, Loi S, Theall KP, Kim S, Huang X, Bananis E, Mahtani R, Finn RS, Diéras V. The effects of adding palbociclib to endocrine therapy to treat advanced breast cancer: a plain language summary of a study using the PALOMA-2 and PALOMA-3 trial results. Future Oncol. 2023 Nov 2. doi: 10.2217/fon-2023-0407. Epub ahead of print. PMID: 37916267.

Tags: Advanced breast cancer, Endocrine therapy, Hematology/Oncology, HR+/HER2–, lay summary, Palbociclib, plain language summary, Publications

Chemotherapy-Induced Biological Age Acceleration and Lifetime Outcomes in Breast Cancer Survivors

Sarkar S, Sedrak MS, Carroll JE, Schechter C, Muss HB, Mandelblatt JS. Chemotherapy-Induced Biological Age Acceleration and Lifetime Outcomes in Breast Cancer Survivors. JAMA Netw[...]

Engineered stem cell-derived CD16-enhanced universal NKT cells improve monoclonal antibody-based cancer immunotherapy

Li YR, Zhu Y, Yu Y, Kramer A, Shao Z, Chen Y, Shen X, Zhang C, Ma N, Zhao A, Ochoa CJ, DiBernardo GA, Yuen[...]

daNIS-2: a phase III, randomized, double-blind study of the anti-TGF-β monoclonal antibody NIS793 or placebo in combination with nab-paclitaxel/gemcitabine as first-line treatment in patients with metastatic pancreatic ductal adenocarcinoma

Paulson S, Ikeda M, Shen L, Stein A, Macarulla T, Milella M, Golan T, Wainberg Z, Taieb J, Wang L, Polydoros F, Abecunas C, López[...]